Pulse Biosciences (NASDAQ:PLSE) issued its earnings results on Monday. The company reported ($0.54) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.45) by ($0.09), MarketWatch Earnings reports.
Shares of Pulse Biosciences stock traded down $3.31 during trading hours on Tuesday, hitting $31.14. The company’s stock had a trading volume of 3,389 shares, compared to its average volume of 181,818. Pulse Biosciences has a twelve month low of $5.11 and a twelve month high of $45.82. The firm has a fifty day moving average of $32.71 and a 200-day moving average of $18.79. The stock has a market cap of $789.15 million, a price-to-earnings ratio of -14.22 and a beta of 1.88.
Separately, HC Wainwright upped their price target on Pulse Biosciences from $40.00 to $46.00 and gave the company a “buy” rating in a research note on Thursday, February 4th.
Pulse Biosciences, Inc operates as a novel bioelectric medicine company. It engages in the research and development, and commercialization of CellFX system that provides a precise and non-thermal cellular treatment technology delivering nanosecond duration energy pulses that impact cells in treated tissue while sparing surrounding non-cellular tissue primarily for dermatology applications.
Featured Article: Certificate of Deposit (CD) For Risk Adverse Investors?
Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.